RDTCF (Rapid Dose Therapeutics) ROCE %: 0.00% (As of Nov. 2025)


RDTCF Rapid Dose Therapeutics Corp RDTCF
27 GF Score
Price $0.08
GF Value $0.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics ROCE %?

Rapid Dose Therapeutics RDTCF 27 ROCE % is 0.00% as of Nov. 2025. GuruFocus rates RDTCF with a GF Score™ of 27/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rapid Dose Therapeutics's annualized ROCE % for the quarter that ended in Nov. 2025 was 0.00%.

Rapid Dose Therapeutics  (OTCPK:RDTCF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rapid Dose Therapeutics ROCE % Related Terms

Rapid Dose Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics ROCE % Chart

Rapid Dose Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -925.80 -8,371.97 0.00 0.00 0.00

Rapid Dose Therapeutics Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RDTCF
27GF Score
Rapid Dose Therapeutics Corp RDTCF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics ROCE % Calculation

Rapid Dose Therapeutics's annualized ROCE % for the fiscal year that ended in Feb. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Feb. 2025 )  (A: Feb. 2024 )(A: Feb. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Feb. 2025 )  (A: Feb. 2024 )(A: Feb. 2025 )
=-2.918/( ( (1.396 - 2.161) + (1.143 - 4.784) )/ 2 )
=-2.918/( (-0.765+-3.641)/ 2 )
=-2.918/-2.203
=132.46 %

Rapid Dose Therapeutics's ROCE % of for the quarter that ended in Nov. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Nov. 2025 )  (Q: Aug. 2025 )(Q: Nov. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Nov. 2025 )  (Q: Aug. 2025 )(Q: Nov. 2025 )
=-1.956/( ( (3.08 - 5.712) + (2.696 - 5.859) )/ 2 )
=-1.956/( ( -2.632 + -3.163 )/ 2 )
=-1.956/-2.8975
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Nov. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Rapid Dose Therapeutics (RDTCF) has a ROCE % of 0.00% as of Nov. 2025.
Is Rapid Dose Therapeutics' ROCE % too high?
Rapid Dose Therapeutics' current ROCE % is 0.00%. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' ROCE % compare to VRTX and REGN?
Rapid Dose Therapeutics' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Rapid Dose Therapeutics's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current ROCE % is 0.00%. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current ROCE % is 0.00% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • ROCE %: 0.00%
  • GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score

Get the complete analysis for RDTCF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.30
GF Value